Stock Price Quote

INDOCO REMEDIES LTD.

NSE : INDOCOBSE : 532612ISIN CODE : INE873D01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE333.751.85 (+0.56 %)
PREV CLOSE ( ) 331.90
OPEN PRICE ( ) 335.95
BID PRICE (QTY) 332.35 (20)
OFFER PRICE (QTY) 333.45 (43)
VOLUME 1642
TODAY'S LOW / HIGH ( )333.00 335.95
52 WK LOW / HIGH ( )286.5 416.95
NSE333.201.95 (+0.59 %)
PREV CLOSE( ) 331.25
OPEN PRICE ( ) 334.05
BID PRICE (QTY) 333.00 (13)
OFFER PRICE (QTY) 333.20 (156)
VOLUME 14641
TODAY'S LOW / HIGH( ) 332.35 334.95
52 WK LOW / HIGH ( )286.6 415
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1947
Management Info
Suresh G Kare - Chairman Aditi Panandikar - Managing Director
Registered Office

Address Indoco House,166 C S T Road,Kalina , Santacruz (East),
Mumbai,
Maharashtra-400098

Phone 022-62871000 / 68791250

Email compliance.officer@indoco.com

Website www.indoco.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX

NEWS

10Jul Indoco Remedies informs about board me
Indoco Remedies has informed that the meeting of the Board of Directors..
10Jun Indoco Remedies informs about disclosu
Indoco Remedies has informed that the Exchange has received the disclosu..
06Jun Indoco Remedies gets USFDA’s tentative
Indoco Remedies has received tentative approval from the US Food and Dru..
06Jun Indoco Remedies jumps on getting USFDA
Indoco Remedies is currently trading at Rs. 317.95, up by 8.70 points or..
06Jun Indoco Remedies informs about press r
Indoco Remedies has informed that it enclosed a Press release regarding..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit375.61166.4
Gross Profit 465 1532.2
Operating Profit 614.12664.9
Net Sales 4454.917908.1

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  8540.00 (2.82%)
M.Cap ( in Cr)10820.66
Abbott India (BSE)
peergroup  28670.35 (0.28%)
M.Cap ( in Cr)60743.25
Astrazeneca Pharma I (BSE)
peergroup  6693.35 (1.03%)
M.Cap ( in Cr)16672.63
Caplin Point Lab (BSE)
peergroup  1585.50 (4.40%)
M.Cap ( in Cr)11958.70
Pfizer (BSE)
peergroup  5006.35 (1.29%)
M.Cap ( in Cr)22979.09

Shareholding Pattern

PROMOTERS 58.72%
NON-INSTITUTION 19.95%
MUTUAL FUNDS/UTI 17.91%
FI/BANKS/INSURANCE 0.29%
GOVERNMENT 0%
FII 0%

About Indoco Remedies Ltd.

Indoco Remedies Ltd. was incorporated in the year 1947. Its today's share price is 333.75. Its current market capitalisation stands at Rs 3078.42 Cr. In the latest quarter, company has reported Gross Sales of Rs. 16666.91 Cr and Total Income of Rs.16693.13 Cr. The company's management includes Satish Shenoy, Ajay Mulgaokar, Ramanathan Hariharan, Anand Nadkarni, Abhijit Y Gore, Vasudha V Kamat, Sundeep V Bambolkar, Aditi Panandikar, Suresh G Kare.

It is listed on the BSE with a BSE Code of 532612 , NSE with an NSE Symbol of INDOCO and ISIN of INE873D01024. It's Registered office is at Indoco House,166 C S T Road,Kalina , Santacruz (East)Mumbai-400098, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Gokhale & Sathe, Patkar & Pendse

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.